A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle.

Authors:
Lindsay M Fry
Lindsay M Fry
Washington State University
United States
David R Herndon
David R Herndon
Washington State University
United States
Valentina Franceschi
Valentina Franceschi
Università di Parma
Italy
David A Schneider
David A Schneider
Washington State University
United States
Gaetano Donofrio
Gaetano Donofrio
Università di Parma
Donald P Knowles
Donald P Knowles
Washington State University
United States

PLoS One 2019 19;14(4):e0215605. Epub 2019 Apr 19.

Department of Veterinary Microbiology & Pathology, Washington State University, Pullman, Washington, United States of America.

Recombinant herpesvirus vaccine vectors offer distinct advantages in next-generation vaccine development, primarily due to the ability to establish persistent infections to provide sustainable antigen responses in the host. Recombinant bovine herpesvirus-4 (BoHV-4) has been previously shown to elicit protective immunity in model laboratory animal species against a variety of pathogens. For the first time, we describe the induction of antigen-specific immune responses to two delivered antigens in the host species after intranasal nebulization of recombinant BoHV-4 expressing the chimeric peptide containing the bovine viral diarrhea virus (BVDV) glycoprotein E2 and the bovine herpesvirus 1 (BoHV-1) glycoprotein D (BoHV-4-A-CMV-IgK-gE2gD-TM). In this study, four cattle were immunized via intranasal nebulization with the recombinant BoHV-4 construct. Two of the cattle were previously infected with wild-type BoHV-4, and both developed detectable serologic responses to BVDV and BoHV-1. All four immunized cattle developed detectable viral neutralizing antibody responses to BVDV, and one steer developed a transient viral neutralizing response to BoHV-1. Approximately one year after immunization, immunosuppressive doses of the glucocorticoid dexamethasone were administered intravenously to all four cattle. Within two weeks of immunosuppression, all animals developed viral neutralizing antibody responses to BoHV-1, and all animals maintained BVDV viral neutralizing capacity. Overall, nebulization of BoHV-4-A-CMV-IgK-gE2gD-TM persistently infects cattle, is capable of eliciting antigen-specific immunity following immunization, including in the presence of pre-existing BoHV-4 immunity, and recrudescence of the virus boosts the immune response to BoHV-4-vectored antigens. These results indicate that BoHV-4 is a viable and attractive vaccine delivery platform for use in cattle.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215605PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474629PMC
April 2019

Publication Analysis

Top Keywords

viral neutralizing
20
neutralizing antibody
12
intranasal nebulization
12
nebulization recombinant
8
antibody responses
8
recombinant bohv-4
8
recombinant bovine
8
developed detectable
8
bovine herpesvirus-4
8
responses bvdv
8
cattle
7
viral
6
bohv-4
6
neutralizing
5
responses
5
recombinant
5
bvdv bohv-1
4
immunized cattle
4
bohv-1 immunized
4
year immunization
4

References

(Supplied by CrossRef)
Pathogenesis of gammaherpesvirus infections
M Ackermann et al.
Veterinary microbiology 2006
Studies of in vivo distribution of bovine herpesvirus type 4 in the natural host
L Egyed et al.
Journal of clinical microbiology 1996

Similar Publications